In the world of performance research, few compounds have generated as much scientific interest as Selective Androgen Receptor Modulators. And among SARMs, RAD-140 (Testolone) stands out as one of the most potent and well-studied.
But what exactly is RAD-140? What does the research show? And why has it become such a focus of scientific investigation?
The Science of Selective Targeting
The key innovation of SARMs lies in their tissue selectivity. Traditional androgens like testosterone affect every tissue with androgen receptors. SARMs, by contrast, are designed to preferentially activate receptors in muscle and bone while having reduced activity elsewhere.
Research indicates RAD-140 demonstrates one of the highest selectivity ratios among studied SARMs—meaning its anabolic-to-androgenic ratio in experimental models is particularly favourable.
What Research Shows
Studies demonstrate that RAD-140 binds to androgen receptors with high affinity. Research published in peer-reviewed journals shows it activates receptors in muscle tissue while showing reduced activity in prostate tissue—the hallmark of SARM selectivity.
High-affinity, tissue-selective binding documented
Preclinical research has examined RAD-140's effects on lean mass in animal models. Studies show significant anabolic activity—increases in lean body mass comparable to testosterone but with a more favourable selectivity profile.
Anabolic effects documented in research models
Emerging studies have investigated RAD-140's potential neuroprotective properties. Research suggests it may have protective effects in neuronal cell models—an area of significant scientific interest given the role of androgens in brain health.
Neuroprotection pathway research ongoing
Research has examined RAD-140's effects on bone tissue. Studies indicate anabolic activity in bone—potentially relevant for research into conditions involving bone loss.
Bone anabolic activity observed in studies
RAD-140 vs. Traditional Androgens
| Factor | RAD-140 | Testosterone |
|---|---|---|
| Administration | Oral | Injection/Topical |
| Tissue Selectivity | High (muscle/bone preferential) | Non-selective |
| Prostate Activity | Reduced in studies | Full androgenic effect |
| Aromatisation | Does not aromatise | Converts to estrogen |
| Research Stage | Investigational | Established |
How RAD-140 Works
- Binds to Androgen Receptors - Selectively attaches to AR in target tissues
- Tissue-Selective Activation - Preferentially activates receptors in muscle and bone
- Reduced Off-Target Activity - Shows lower activity in prostate and other tissues
- No Aromatisation - Does not convert to estrogen like testosterone
- Oral Bioavailability - Active when taken orally, unlike many androgens
Areas of Scientific Interest
Researchers continue to investigate RAD-140 across multiple domains:
- Muscle wasting conditions - Original development focus
- Sarcopenia research - Age-related muscle loss
- Bone density studies - Potential bone-protective effects
- Neuroprotection - Brain health and androgen receptor activity
- Breast cancer research - Radius Health's clinical focus
Why RAD-140 Interests Researchers
The scientific interest in RAD-140 comes down to its unique profile:
- High selectivity ratio - Among the most selective SARMs studied
- Oral bioavailability - Convenient for research protocols
- Well-characterised - Extensive preclinical data available
- Multiple research applications - Muscle, bone, and neuro studies
- Favourable pharmacokinetics - Suitable half-life for research
For researchers investigating androgen receptor biology, tissue-selective compounds, or anabolic mechanisms, RAD-140 represents one of the most studied tools available.